New FDA Approvals
New FDA Approvals
These drugs have received final approval from the U.S. Food and Drug Administration (FDA):
- Dementia agent Exelon (rivastigmine tartrate) by Novartis Pharmaceuticals. Exelon is a reversible cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. Exelon is dosed twice daily and is available in 1.5, 3.0, 4.5, and 6.0 mg capsules.
- Selective H1-receptor antagonist Optivar (azelastine hydrochloride ophthalmic solution) 0.05% by Muro Pharmaceutical Inc. Optivar has received FDA approval for the treatment of itching of the eye associated with allergic conjunctivitis. It is administered topically to the eyes twice daily.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.